Abivax SA

Abivax SA’s stock price surged over 500% after the company announced positive results from its Phase 3 clinical trials for its ulcerative colitis drug, Obefazimod.

Abivax SA, a Paris-based biotech firm, navigates financial uncertainty while advancing its innovative pipeline of anti-viral therapies and vaccines.